Body composition during treatment with lumacaftor/ivacaftor in 24 adults# with cystic fibrosis
| Baseline | 1 month | 6 months | 1 year | p-value | |
| Weight kg | 58.4±12.1 | 59.0±11.3 | 60.6±10.9** | 60.8±11.1 | 0.0007 |
| Fat-free mass kg | 46.1±11.2 | 45.8±10.9 | 46.7±11.0 | 46.2±10.7 | 0.49 |
| Fat mass kg | 12.5±6.7 | 13.5±6.4 | 14.0±5.8** | 14.7±6.3*** | <0.0001 |
| BMI kg·m−2 | 20.3±2.7 | 20.5±2.4 | 21.1±2.1* | 21.2±2.3** | 0.0003 |
| FFMI kg·m−2 | 15.9±2.5 | 15.8±2.4 | 16.1±2.4 | 16.0±2.3 | 0.48 |
| FMI kg·m−2 | 4.4±2.4 | 4.8±2.4 | 4.9±2.2** | 5.2±2.4*** | <0.0001 |
| TBW L | 33.7±8.1 | 33.6±7.7 | 34.2±7.9 | 33.9±7.8 | 0.46 |
| ICW L | 19.2±5.5 | 19.2±5.5 | 19.7±5.3 | 19.5±5.2 | 0.27 |
| ECW L | 14.5±2.8 | 14.4±2.7 | 14.5±2.8 | 14.4±2.8 | 0.84 |
| ECW % TBW | 43.6±3.9 | 43.3±3.4 | 42.8±3.8 | 43.0±3.5 | 0.29 |
| Phase angle ° | 4.8±0.9 | 4.8±0.9 | 4.7±1.4 | 4.8±0.9 | 0.08 |
Data are presented as mean±sd, unless otherwise stated. BMI: body mass index; FFMI: fat-free mass index; FMI: fat mass index; TBW: total body water; ICW: intracellular water; ECW: extracellular water. #: n=24 for weight and BMI for all time-points, and for all data at 1 year; n=23 for all other measurements at baseline, 1 month and 6 month time-points (for one patient, useable bioelectrical impedance analysis could not be obtained at baseline and 1 month, and one patient missed the 6-month measurement). Individual p-values for change between baseline and that time-point (derived from the regression model with Bonferroni correction): *: p<0.05; **: p<0.005; ***: p<0.0001. Overall p-value is for the linear mixed effects regression model for effect of time on variables.